Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan

Zahid, Mohammad Faizan; Ali, Natasha; Nasir, Myra; Baig, Maria Haider; Iftikhar, Mustafa; Mahmood, Syed Usman Bin; Malik, Arhama; Atif, S; Beg, Mohammad Asim

doi:10.1016/j.htct.2019.02.005

Cited by 9 publications

(2 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, in 65.5% of cases, the organism was not identified. Infection was the principal reason of death in 6.3% out of all subjects ( 16 ). In MM subjects, risk elements of infection were Durie-Salmon stage IIIB, neutropenia, sex (female), augmented serum creatinine, bad performance status and the presence of a catheter indwelling ( 17 ).…”

Section: Characteristics Of Secondary Immunodeficiency In Patients With Multiple Myelomamentioning

confidence: 99%

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

et al. 2021

View full text Add to dashboard Cite

Secondary immunodeficiency is reported in most patients with hematological malignancies such as chronic lymphocytic leukemia and multiple myeloma. The aim of our review was to evaluate the existing literature data on patients with hematological malignancies, with regard to the effect of immunodeficiency on the outcome, the clinical and therapeutic approach, and on the onset of noninfectious complications, including thrombosis, pleural effusion, and orofacial complications. Immunodeficiency in these patients has an intense impact on their risk of infection, in turn increasing morbidity and mortality even years after treatment completion. However, these patients with increased risk of severe infectious diseases could be treated with adequate vaccination coverage, but the vaccines’ administration can be associated with a decreased immune response and an augmented risk of adverse reactions. Probably, immunogenicity of the inactivated is analogous to that of healthy subjects at the moment of vaccination, but it undertakes a gradual weakening over time. However, the dispensation of live attenuated viral vaccines is controversial because of the risk of the activation of vaccine viruses. A particular immunization schedule should be employed according to the clinical and immunological condition of each of these patients to guarantee a constant immune response without any risks to the patients’ health.

show abstract

Section: Characteristics Of Secondary Immunodeficiency In Patients With Multiple Myelomamentioning

confidence: 99%

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Increased susceptibility to infections in MM patients is associated with B‐cell dysfunction, such as hypogammaglobulinaemia, as well as abnormalities in T, dendritic and NK cells. Moreover, anti‐MM therapies may increase the risk for infections, 6–9 …”

Section: Introductionmentioning

confidence: 99%

Invasive Pulmonary Aspergillosis in Multiple Myeloma patients: A sizeable diagnosis in the era of novel anti‐myeloma therapies

Fuchs

Lavi

Carasso

et al. 2021

Mycoses

View full text Add to dashboard Cite

Background Advances in treatment for multiple myeloma (MM) patients entail a high risk for opportunistic infections such as invasive pulmonary aspergillosis (IPA). Objectives This study was conducted to describe the patient's profile, clinical manifestations, diagnosis and outcome of MM patients with IPA, in our large haemato‐oncology centre. Patients/Methods We retrospectively analysed patients with MM who underwent Broncho alveolar lavage for pneumonia at Rambam Hospital during a 13‐year period from July 2005 to February 2018. We focused on those with Aspergillus pneumonia. Results Of the 669 patients with multiple myeloma, mean age 62.6 (±7.6) years, forty‐two patients (6.2%) were diagnosed with IPA. Among them, 60% had a probable diagnosis and 40% possible. Clinical presentation was similar for IPA and other pulmonary infections. Compared to those with other pulmonary infections, IPA was more commonly diagnosed in patients with long‐standing disease (p = .00012) and among patients receiving 3 or more lines of myeloma therapies (p = .04). Thirty‐day mortality rates following diagnostic bronchoscopy did not differ between IPA and non‐IPA patients. (p = .85). Conclusions Multiple myeloma patients had an increased risk for IPA, most notably in patients with 3 or more lines of anti‐myeloma treatment and more advanced disease. This clearly emphasises the vigilance needed for IPA in these patients.

show abstract

A Multicenter Study of Clinical Presentations and Outcomes of Multiple Myeloma in Pakistan: The Real-World Analysis in a Resource-Constrained Country

Saeed

Ahmad

Moosajee

et al. 2021

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Infections in patients with multiple myeloma treated with conventional chemotherapy: a single-center, 10-year experience in Pakistan

Cited by 9 publications

References 31 publications

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

Secondary Immunodeficiency in Hematological Malignancies: Focus on Multiple Myeloma and Chronic Lymphocytic Leukemia

Invasive Pulmonary Aspergillosis in Multiple Myeloma patients: A sizeable diagnosis in the era of novel anti‐myeloma therapies

A Multicenter Study of Clinical Presentations and Outcomes of Multiple Myeloma in Pakistan: The Real-World Analysis in a Resource-Constrained Country

Contact Info

Product

Resources

About